|

Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization

RECRUITINGN/ASponsored by Taichung Tzu Chi Hospital
Actively Recruiting
PhaseN/A
SponsorTaichung Tzu Chi Hospital
Started2023-01-01
Est. completion2025-12-31
Eligibility
Age20 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07178093

Summary

Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization

Eligibility

Age: 20 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Sign the informed consent form
* Aged between 20 and 80
* Child-Pugh score class A, B
* Serum bilirubin level ≤ 1.5 times the upper limit of normal, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤ 2 times the upper limit of normal

Exclusion Criteria:

* Unwillingness to sign the informed consent form
* Child-Pugh score class C
* Patients with main portal vein thrombosis
* Patients with diffuse liver tumors
* Those who are allergic to the contrast medium
* Those with abnormal coagulation function
* Those with severe dysfunction of brain, heart and lung
* Patients with severe renal dysfunction (except those receiving renal dialysis)
* Unable to cooperate
* Those with uncontrolled arrhythmia and unstable blood pressure
* Some patients with abnormal thyroid function
* Any other contraindications such as active gastrointestinal bleeding, refractory ascites, or severe portal hypertension
* Pregnant or lactating women

Conditions5

CancerHepatocellular CarcinomaLiver CancerLiver DiseaseTransarterial Chemoembolization

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.